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Objectives: Immunohistochemistry for DNA mismatch
repair proteins is used to screen for Lynch syndrome
in individuals with colorectal carcinoma (CRC).
Although solitary loss of PMS2 expression is indicative
of carrying a germline mutation in PMS2, previous
studies reported MLH1 mutation in some cases. We
determined the prevalence of MLH1 germline
mutations in a large cohort of individuals with a CRC
demonstrating solitary loss of PMS2 expression.
Design: This cohort study included 88 individuals
affected with a PMS2-deficient CRC from the Colon
Cancer Family Registry Cohort. Germline PMS2
mutation analysis (long-range PCR and multiplex
ligation-dependent probe amplification) was followed
by MLH1 mutation testing (Sanger sequencing and
multiplex ligation-dependent probe amplification).
Results: Of the 66 individuals with complete mutation
screening, we identified a pathogenic PMS2 mutation
in 49 (74%), a pathogenic MLH1 mutation in 8 (12%)
and a MLH1 variant of uncertain clinical significance
predicted to be damaging by in silico analysis in 3
(4%); 6 (9%) carried variants likely to have no clinical
significance. Missense point mutations accounted for
most alterations (83%; 9/11) in MLH1. The MLH1
c.113A> G p.Asn38Ser mutation was found in 2 related
individuals. One individual who carried the MLH1
intronic mutation c.677+3A>G p.Gln197Argfs*8
leading to the skipping of exon 8, developed 2
tumours, both of which retained MLH1 expression.
Conclusions: A substantial proportion of CRCs with
solitary loss of PMS2 expression are associated with a
deleterious MLH1 germline mutation supporting the
screening for MLH1 in individuals with tumours of this
immunophenotype, when no PMS2 mutation has been
identified.
INTRODUCTION
Lynch syndrome is an autosomal-dominant
inherited condition defined by the identifica-
tion of a germline mutation in a DNA mis-
match repair (MMR) gene (MLH1, MSH2,
PMS2 or MSH6), or in the EPCAM gene,
leading to constitutional epigenetic silencing
of the downstream MSH2 gene.1 Individuals
who carry a MMR gene mutation are at an
increased risk of developing cancers at mul-
tiple sites, most notably colorectal and endo-
metrial carcinomas, but also carcinomas
from the upper urinary tract, pancreas, hepa-
tobiliary tract, stomach, small intestine and
ovaries.2
The current diagnostic approach for the
identification of individuals with an MMR
Strengths and limitations of this study
▪ Largest reported sample of colorectal cancers
with solitary loss of PMS2 expression.
▪ Most comprehensive approaches used for testing
for germline PMS2 mutations.
▪ Multicentre setting which may affect the consist-
ency in the formalin fixation conditions of tissue
blocks and lead to immunostaining artefacts.
▪ No mutation screening data available for 20
cases (24%).
▪ Selected cases (young individuals with strong
family history of colorectal carcinoma (CRC))
that may not reflect the actual rate of
PMS2-deficient CRC in the general population
and the mutation rates in PMS2 and MLH1.
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gene mutation is a multistep process in which patholo-
gists play an instrumental role. Tumours arising in indivi-
duals with an MMR gene mutation demonstrate high
levels of microsatellite instability (MSI) secondary to
altered DNA MMR mechanisms in tumour cells.
Immunohistochemistry for DNA MMR proteins is widely
used to identify MMR deficiency in colorectal carcin-
omas (CRCs) as a screen for MMR gene carriers.3 Of all
abnormal patterns of immunohistochemical results, loss
of expression of MLH1 and PMS2 is the most common.
MLH1 and PMS2 function as a stable heterodimer that,
along with MSH2, MSH6 and EXO1, corrects small
errors involving mispaired nucleotides which are intro-
duced by DNA polymerase during DNA replication. A
functional defect in MLH1 results in the degradation of
both MLH1 and PMS2, whereas a defect in PMS2 results
only in the degradation of PMS2. Consequently, loss of
expression of MLH1 and PMS2 in CRC generally indi-
cates an alteration in MLH1, either by somatic methyla-
tion of the MLH1 promoter region (sporadic cases) or
by a MLH1 germline mutation (Lynch syndrome), and
solitary loss of PMS2 expression generally indicates an
underlying germline defect in PMS2.
Inconsistent immunohistochemical results have been
reported, in particular the retained expression of MLH1
in tumours from individuals with a germline MLH1
mutation.4–8 This phenomenon can be misleading if
PMS2 immunostaining is not performed. We sought to
confirm that germline mutations in MLH1 may underlie
a substantial proportion of CRC with solitary loss of
PMS2 expression. To address this question, we per-
formed mutation analysis of the MLH1 and PMS2 genes
in individuals from the Colon Cancer Family Registry
Cohort whose tumours showed solitary loss of PMS2.
MATERIALS AND METHODS
Study participants
Participants were probands and relatives from families
recruited between 1997 and 2012 to the Colon Cancer
Family Registry Cohort via both population-based
recruitment and clinic-based recruitment in Australasia
and North America.9 All CRC cases were reviewed by
specialist gastrointestinal pathologists for histological
type and grade.10 Tumours from the caecum, ascending
colon, hepatic flexure and transverse colon were consid-
ered proximal tumours. Immunohistochemistry for DNA
MMR proteins MLH1, PMS2, MSH2 and MSH6 was per-
formed as previously described.3 A subset of tumours
were analysed for MSI status from formalin-fixed
paraffin-embedded tissue as previously described.3
Individuals were eligible for this study if they had a histo-
logically confirmed diagnosis of CRC with an immuno-
histochemical profile of the DNA MMR proteins,
demonstrating presence of expression of the MLH1
protein and concomitant loss of expression of the PMS2
protein. The somatic T> A mutation at nucleotide 1799
in exon 15 of the BRAF gene (BRAFV600E mutation) was
detected using fluorescent allele-specific PCR.11 MLH1
promoter methylation was analysed using the MLH1-M2
methylight reaction using an Arthobacter luteus (ALU)
control reaction to normalise for bisulfite-converted input
DNA.12 Informed consent was obtained from all partici-
pants to collect a blood sample and tumour pathology
materials (tumour blocks and slides). Ethics approval
was obtained from the relevant institutional Human
Research Ethics Committees at recruiting centres.
Family history of cancer
Information on personal and family history of CRC and
other cancers in first-degreeand second-degree relatives
was obtained via standardised questionnaires at the time
of baseline recruitment. Cancer diagnoses were verified,
where possible, using pathology reports, medical
records, cancer registry reports and death certificates.
Probands and relatives were either actively or passively
followed up approximately every 5 years from baseline
enrolment, including the collection of updated informa-
tion by linkage to tumour registries and death indices
on the number, sex and birthdates of first-degree rela-
tives, their cancer history, vital status and, if deceased,
date of death. All cancers, except for non-melanoma
skin cancers, were recorded with dates of diagnosis. The
present study was based on all available baseline and
follow-up data. Family history of cancer that fulfilled
either the Amsterdam I or II criteria were determined.13
Germline mutation testing
Germline mutation testing for the individuals in this
study primarily involved testing for PMS2 gene mutations
and when a PMS2 mutation was not identified, germline
mutation testing of the MLH1 gene was conducted.
PMS2 was screened for germline mutations using a
DNA-based, best practice, approach combining long-
range PCR and multiplex ligation-dependent probe
amplification (MLPA). Briefly, for point mutation ana-
lysis, parts of the PMS2 gene (exons 1–5, 9 and 11–15)
were specifically targeted, while avoiding pseudogene
sequences, via a set of three long-range PCRs (TaKaRa
LA Taq; TaKaRa Bio Inc, Shiga, Japan). These long-
range products are then used as the template for a set of
PMS2-specific exonic PCRs (see online supplementary
table S1 for primer sequences). To assess for large-scale
(whole exon) deletions, we used the P008-B1 MLPA kit
according to the manufacturer’s instructions
(MRC-Holland; Amsterdam, The Netherlands). To
accurately call PMS2 mutations at the 3′ end of the
gene, the MLPA kit contains probes targeted to
paralogous sequence variants which requires
pseudogene-specific sequence data to interpret the find-
ings. Pseudogene sequences were obtained as above,
replacing the PMS2-specific long-range amplicon with a
pseudogene-specific amplicon. Germline mutation
testing for MLH1 was performed by Sanger sequencing
as previously described.9 14 Large duplication and dele-
tion mutations were detected by MLPA. Germline
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variants within the MLH1 and PMS2 genes were classi-
fied for pathogenicity based on the InSiGHT database
classifications15 (http://insight-group.org/variants/
classifications/). If no classification was available,
the predicting effect of an unclassified variant (UV) to
the protein function was assessed in silico using the
‘Sorting Tolerant From Intolerant’ (SIFT) and the
‘Polymorphism Phenotyping v2’ (PolyPhen-2) web-based
algorithms.16 17
Statistical analysis
Statistical analyses were performed with SPSS statistics
software V.17.0 (SPSS Inc, Chicago, Illinois, USA).
Comparisons for categorical variables were performed
using Pearson’s χ2 test or Fisher’s exact test where appro-
priate. Student t test was used for continuous variables.
A two-tailed p value was used for all analyses and values
less than 0.05 were considered to be significant.
RESULTS
The study included 90 CRCs from 88 individuals demon-
strating loss of PMS2 expression and normal retained
MLH1 expression by immunohistochemistry. They had a
mean age at CRC diagnosis of 51.7±SD 12.4 years and
included 57% males. MSI status was available for 46/90
CRCs (51%), with high levels of MSI observed in 42/46
(91%) cases. MLH1 methylation and/or a BRAFV600E
mutation were present in 4 of the 90 CRCs that were
excluded from the study. Six CRCs (7%) also showed
loss of MSH6 protein expression. Four individuals were
not tested for PMS2 and MLH1 mutations due to the
unavailability of blood-derived DNA, and complete gene
testing was not possible for a further 14 individuals
(figure 1). The final study group consisted of 66 indivi-
duals with complete screening for germline mutations
in the PMS2 and MLH1 genes. A pathogenic PMS2
germline mutation was identified in 49 individuals
(74%; see online supplementary table S2), some of
which were reported previously.18 Variants in the MLH1
gene were identified in 11 individuals (17%). In eight
individuals, the variants were classified as pathogenic
mutations (class 5); in the other three individuals, var-
iants were unclassified but predicted to be damaging by
SIFT and PolyPhen-2 algorithms (table 1 and figure 2).
Immunostained slides were reviewed in 5 of these 11
cases, confirming the retained expression of MLH1 and
the loss of PMS2 expression in carcinoma cells. No
mutation within PMS2 or MLH1 could be found in the
remaining six individuals (9%). The clinicopathological
characteristics of the PMS2 mutation carriers, the MLH1
pathogenic mutation and UV carriers and those indivi-
duals tested but found not to have a mutation in PMS2
or MLH1 are shown in table 2.
The mean age at CRC diagnosis of the individuals
with a MLH1 mutation or UV was significantly younger
than those individuals with a PMS2 mutation (p=0.046).
Amsterdam criteria I or II were less frequently found in
PMS2 mutation carriers compared with MLH1 variant
carriers (p=0.001).
Missense variants were the most common MLH1 alter-
ation identified, in eight individuals (83%). The MLH1
c.113A>G p.Asn38Ser variant was found in two related
individuals (cases 2 and 3). One individual who carried
the intronic MLH1 germline mutation c.677+3A>G p.
Gln197Argfs*8, which leads to the skipping of exon 8,
developed two CRCs both of which retained MLH1
expression (cases 5 and 6). One individual carried a
splice site mutation leading to an in-frame deletion of
two exons (case 4) and one individual carried a small
insertion resulting in a frameshift mutation (case 7;
table 1).
DISCUSSION
To assess the possible role of MLH1 mutations in CRCs
showing solitary loss of PMS2 expression by immunohis-
tochemistry, we studied a series of 90 CRCs from 88 indi-
viduals from the Colon Cancer Family Registry Cohort
with this immunophenotype. Among the 66 individuals
with complete germline mutation analysis, we identified
a pathogenic PMS2 mutation in 49 cases (74%) and a
pathogenic MLH1 mutation in 8 cases (12%). A further
three cases (4%) had a variant of uncertain clinical sig-
nificance in MLH1 predicted to be damaging, and six
cases (9%) had no identifiable variant likely to have clin-
ical significance in either gene. Moreover, a high pro-
portion of the MLH1 variants identified resulted in
missense changes, suggesting that a non-functional
MLH1 protein that retains its MLH1 antigenicity is a
conceivable explanation.
Immunohistochemistry for the DNA MMR proteins
MLH1, PMS2, MSH2 and MSH6 in CRC is a highly sen-
sitive test to screen for Lynch syndrome, with 93–100%
concordance with MSI testing.3 4 However, false-negative
results for MLH1 immunohistochemistry have been
reported in small series. In a study evaluating the
benefit of adding PMS2 to MLH1 staining, de Jong et al4
found eight MLH1 mutations (42%) compared with
only three PMS2 mutations (16%) out of 19 CRCs dem-
onstrating solitary loss of PMS2 expression. When con-
sidering all the MLH1 mutations identified in their
study, a high proportion (8/35; 23%) showed loss only
of PMS2 expression while retaining expression of
MLH1. A large deletion of exons 14–19 of MLH1 was
also reported in 2 of 8 (25%) CRC with solitary PMS2
loss of expression in a separate study.5 A recent study of
16 CRCs and 16 endometrial carcinomas from 31 indivi-
duals, all with solitary loss of PMS2 expression, explored
the frequency of MLH1 mutations in this group.19 Of
the 17 individuals who subsequently had germline muta-
tion testing of the MLH1 and PMS2 genes, six had
pathogenic mutations in PMS2 (35%), two had variants
of uncertain clinical significance in PMS2 (12%), four
had MLH1 pathogenic mutations (24%) whereas
five had no mutation identified in either gene (29%).
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When restricted to patients with a CRC, a deleterious
germline mutation in MLH1 was reported in two of nine
tested patients (22%). Compared with these studies, our
rate of PMS2 mutation in 66 tested individuals was
higher at 74% and the rate of MLH1 deleterious muta-
tion slightly lower at 12%. Two cousins (tumours 2 and
3) who carried the same MLH1 mutation both had CRC
with solitary PMS2 loss. Similarly, one individual, who
carried the MLH1 c.677+3A>G p.Gln197Argfs*8 muta-
tion, developed two CRCs with solitary PMS2 loss. Both
these examples suggest that it is the nature of the muta-
tion rather than a technical anomaly associated with
tissue fixation or staining quality that is the cause of this
differential staining pattern. In support of this,
Zighelboim et al20 described two sisters who carried the
same MLH1 mutation: one developed endometrial
cancer at 48 years and the other CRC at 45 years and
endometrial cancer at 53 years; all tumours showed soli-
tary loss of PMS2 expression and the presence of MLH1
expression.
A trend towards universal CRC tumour immunohisto-
chemistry will increase the detection of abnormal stain-
ing patterns that require interpretation. This allows the
most probable cause to be decided and thus the most
appropriate management instituted. A solitary loss of
PMS2 expression is suggestive of Lynch syndrome with a
primary defect in the PMS2 gene. Interestingly, we iden-
tified MLH1 methylation or the somatic BRAFV600E muta-
tion in four cases, indicating that isolated PMS2 loss of
expression can occur outside Lynch syndrome. It may
Figure 1 Flow diagram of the
study. CRC, colorectal carcinoma.
Table 1 Characteristics of the 11 individuals with a germline MLH1 variant from 12 colorectal carcinomas with loss of PMS2











1 Female 40 None Descending c.230G>A p.Cys77Tyr Class 5
2* Male 44 None Descending c.113A>G p.Asn38Ser Class 5
3* Male 40 I Rectum c.113A>G p.Asn38Ser Class 5
4 Female 51 I Descending c.790+1G>A p.Glu227_Ser295del Class 5
5† Male 34 II Cecum c.677+3A>G p.Gln197Argfs*8 Class 5
6† Male 34 II Rectum c.677+3A>G p.Gln197Argfs*8 Class 5
7 Male 63 I Caecum c.2195_2198dup p.His733Glnfs*14 Class 5
8 Male 49 None Unknown c.230G>A p.Cys77Tyr Class 5
9 Female 33 None Rectum c.199G>A p.Gly67Arg Class 5
10 Male 62 II Transverse c.374C>A p.Ala125Glu UV
11 Male 24 None Ascending c.187G>C p.Asp63His UV
12 Male 38 I Cecum c.187G>C p.Asp63His UV
UV: unclassified variant by InSiGHT. These UVs were predicted to be damaging through in silico analysis.
*Cousins.
†2×colorectal carcinomas from the same individual.
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therefore be useful to test PMS2-deficient CRC for
BRAFV600E mutation or MLH1 methylation to exclude
sporadic tumour. Screening for PMS2 mutations has
been problematic due a large number of homologous
sequences within pseudogenes that closely flank the
functional gene and most likely accounts for the lower
proportion of PMS2 mutations reported in previous
studies. The recent development of new methods
incorporating long-range PCR and MLPA has eliminated
most of the previous problems, such that the identifica-
tion of large-scale deletions of exons 3 and/or 4 are now
the only difficulty. The results from this study, represent-
ing the largest number of CRC with solitary loss of
PMS2, support germline mutation screening of MLH1
when no mutation in PMS2 has been found. However, a
substantial proportion of MMR-deficient CRCs with no
evidence of MLH1 methylation or BRAFV600E mutation
remain unexplained and are referred to as Lynch-like or
suspected Lynch syndrome. A number of potential
causes for the underlying loss of PMS2 protein expres-
sion in these cases, including biallelic somatic mutations
and cryptic mutations, have been described in a recent
review.21 In a large population-based study of the Colon
Cancer Family Registry Cohort, 5.6% (271/4 853) of all
CRCs were classified as Lynch-like syndrome, represent-
ing 56% of all MMR-deficient CRCs not secondary to
MLH1 methylation. In our study, six CRCs showed con-
current loss of MSH6 and PMS2. The most likely explan-
ation for the loss of MSH6 expression in these six cases
is the somatic frameshift mutation in the (C)8 microsat-
ellite in exon 5 of the MSH6 gene secondary to the loss
of MMR function resulting from the PMS2 defect.22 The
use of panel testing rather than a single-gene approach
would be useful; this is of particular interest clinically,
where the PMS2 gene has lower penetrance than other
MMR genes23 and family history is a suboptimal way of
finding potentially high-risk families, where risk assess-
ment and risk management has improved outcomes.
However, PMS2 testing remains challenging even by next
generation sequencing due to its complex structure.
Our study included the largest reported sample of
CRCs with solitary loss of PMS2 to date. Testing for
germline PMS2 mutations used in this study employed
the most up-to-date and comprehensive approaches
described,18 24 as demonstrated by the high rate of iden-
tified PMS2 mutations. One limitation of this study is the
multicentre setting which may affect the consistency in
the formalin fixation conditions of tissue blocks and
lead to immunostaining artefacts. Other limitations
include the absence of other Lynch syndrome-associated
tumours, and the lack of mutation screening data for 20
(24%) cases. Moreover, our results may not reflect the
Figure 2 Graphical overview of
the location of the 11 MLH1
mutations identified. Numbers
above the gene schematic denote
the amount of mutations identified
in the corresponding exons.
Mutation subtypes are boxed in
green and the predicted
functional domains of the MLH1
protein are displayed below the
gene schematic.





























Gender male, N (%) 36 (54.5) 26/49 (53.1) 8/11 (72.7) 0.32 2 (33.3)
Amsterdam criteria I, N (%) 6 (9.1) 0 (0) 6 (54.5) 0.001* 0 (0)
Amsterdam criteria II, N (%) 10 (15.2) 4 (8.2) 6 (54.5) 0 (0)
Proximal CRC location, N (%) 42/64 (65.6) 35/47 (74.5) 5/10 (50) 0.14 2/6 (33.3)
Histological type, N (%) 1
Adenocarcinoma 50/63 (79.4) 36/47 (76.6) 9/11 (81.8) 6/6 (100)
Mucinous carcinoma 13/63 (20.6) 11/47 (23.4) 2/11 (18.2) 0/6 (0)
Histological grade, N (%) 0.024
Well/moderate 42/62 (67.7) 36/46 (78.3) 4/10 (40) 1/5 (20)
Poor 20/62 (32.3) 10/46 (21.7) 6/10 (60) 4/5 (80)
*p Value for Amsterdam criteria I or II.
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actual rate of PMS2-deficient CRC in the general popu-
lation and the mutation rates in PMS2 and MLH1, as
these cases were selected in young individuals with
strong family history of CRC.
In conclusion, the findings from this study suggest
that CRCs in MLH1 mutation carriers can demonstrate a
normal pattern of MLH1 expression and justify the
testing for MLH1 germline mutation in individuals with
a CRC showing solitary loss of PMS2 expression when a
PMS2 mutation is not identified.
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